Head-To-Head Survey: Seres Therapeutics (NASDAQ:MCRB) versus Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Aprea Therapeutics and Seres Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1	1	3	0	2.40
Seres Therapeutics	1	1	2	0	2.25

Aprea Therapeutics currently has a consensus price target of $3.07, suggesting a potential upside of 287.50%. Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 221.97%. Given Aprea Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Seres Therapeutics.

Risk and Volatility

Aprea Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Insider & Institutional Ownership

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aprea Therapeutics and Seres Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290,000.00	34.36	-$12.60 million	($1.08)	-0.73
Seres Therapeutics	$790,000.00	67.17	$5.70 million	($2.43)	-2.17

Seres Therapeutics has higher revenue and earnings than Aprea Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aprea Therapeutics and Seres Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Summary

Aprea Therapeutics beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

About Seres Therapeutics

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.